INTRODUCTION

Insulin is an anabolic hormone responsible for the maintenance of glucose homeostasis in the human body. It helps in the uptake of glucose molecules into the tissues and results in the utilization of glucose moity into energy by various biochemical mechanisms [1]. However, lack of adequate insulin levels in our body leads to several chronic metabolic disturbances of carbohydrate, fat, and protein that is often termed as diabetes mellitus (DM) which is a serious and lifelong condition [2]. There are two principal forms of diabetes: type 1 diabetes, in which the pancreas fails to produce insulin, and type 2 diabetes, which results from the body’s inability to respond properly to the action of insulin produced by the pancreas [3]. The prevalence of diabetes has increased globally over the years and it has been noted as one of the leading causes of high mortality and morbidity rate [4]. About 422 million people worldwide have diabetes and 1.6 million deaths are directly attributed to diabetes each year [5]. According to the IDF statistics, adults with type 2 diabetes (T2 DM) outnumber those with type 1 diabetes [6]. Type 2 DM is a heterogenous disorder characterized by multiple problems in the pancreatic β-cell, liver, and peripheral tissue such as skeletal muscles and adipose tissue. These multiple complications are well managed by combination therapy using two antidiabetic drugs. Combination therapy is more advantageous than monotherapy in minimizing problems such as dose-dependent side effects, dosing frequency, etc. A low-dose combination of two different drugs reduces dose-related risks and minimizes the clinical and metabolic side effects that occur with the maximal dosage of individual components as in monotherapy, and thus dosage of the single components can be reduced [7, 8]. Diabetes needs much attention as glucose levels that tend to increase after a meal, have to maintain for the whole day for proper activity of the body [9]. To combat such conditions, sustained-release (SR) formulations that regulate antidiabetic activity round the clock need to develop to optimize the postprandial elevation of glucose levels [10].

Metformin hydrochloride, an oral biguanide first-line choice of drug and gliclazide (GLZ), the second-generation sulphonylurea provides good hypoglycemic excellence by increasing both basal and meal-stimulated insulin secretion along with enhancement of peripheral insulin sensitivity, ultimately leading to declining in fasting, postprandial glucose, and glycosylated hemoglobin (HbA1c) levels [11]. Bilayer technology is one of the suitable approaches for the successful development of sustained-release formulations that provide a way of successful drug delivery. A bilayer tablet is suitable for the fabrication of sustained release dosage form (tablet) consisting of two drugs in combination in two different layers and sequentially release the drugs [12]. The present research aimed to develop a sustained release bilayer formulation using combination therapy, which provides better postprandial hyperglycemic control with a daylong duration and reduces the economic burden in management of diabetes compared to the expenses in marketing new drug entities. The objective of the present investigation is to design and evaluate sustained release bilayer tablets containing metformin hydrochloride and gliclazide.

MATERIALS AND METHODS

Materials

Metformin hydrochloride and gliclazide were supplied as a gift sample from Cipla Pharmaceuticals Ltd., Mumbai. Desai chemicals Ltd remained as a main supplier for the polyox WSR coagulant, HPMC polymers of grade K4M, K15M, K100M and all other excipients used in the study. HPLC grade acetonitrile, potassium dihydrogen phosphate, orthophosphoric acid AR grade purchased from Lotus Chem. Mumbai, India. Waters e2695 separation module with high pressure liquid chromatographic instrument provided with an RP-Select B C18 column (250 mm x 4.6 mm; 5µ) and 2489 UV-Visible detector, auto-injector, an autosampler with Empower 2 software from Waters Corporation, Milford USA was employed in the study.
Methods

Experimental method

Drug-excipient interaction study

It is a critical primary concern for any dosage form to study the compatibility of drug, polymer and other excipients; therefore, it is necessary to confirm that the drug does not interact with polymers and excipients under experimental conditions and affects the shelf life of the product. The drug excipient compatibility has done by physical observation of mixtures for one month and FT-IR study. The drug has mixed with excipients in a different ratio. These mixtures were kept in 5 ml glass white-colored vials and packed properly. These vials were exposed to room temperature and 40°C/75% RH. 2 to 3 g of the blend was prepared and filled in three vials. Observations for any physical change in appearance were performed at zero weeks to one month [13].

FTIR spectroscopy

Fourier transform infrared spectroscopy (FT-IR) investigations were used to detect possible drug-drug and drug-excipient interactions by using an FT-IR spectrometer –430 (Jasco-Japan). The Potassium Bromide pellets, an infrared transparent matrix, were prepared on KBr press on grounding the solid powder sample with 100 times the quantity of KBr in a mortar [14]. The spectra were recorded at a resolution of 4 cm\(^{-1}\) over the wavenumber of 4000 to 400/cm.

Analytical method

Preparation of stock and working standard solution of metformin hydrochloride and gliclazide

A mixture of pH 6.6 phosphate buffer and acetonitrile in the ratio 60:40% v/v filtered through 0.45µ membrane filter used as mobile phase for preparing the working solution of the drug. About 500 mg of metformin hydrochloride and 60 mg of gliclazide were accurately weighed and transferred into a 100 ml volumetric flask; the solution was sonicated and the resulting solution was diluted with the mobile phase to obtain a primary stock solution. 10 ml of this stock solution was further diluted to 10 ml using mobile phase to obtain 500 µg/ml metformin hydrochloride and 60 µg/ml gliclazide. From this solution, suitable working solutions of different concentrations were prepared.

Construction of calibration curve of metformin hydrochloride and gliclazide

Linearity of the peak area response was determined by measuring working standard dilution of metformin hydrochloride and gliclazide in the range of 125-750 µg/ml and 20-120 µg/ml respectively. Triplicate of the 20-µl quantity of each dilution injected each time into the column. The drug in elutes was monitored at 261 nm and the corresponding chromatograms were obtained. From these chromatograms, a plot of amount and response was constructed. The regression equation (fig. 1 and 2) obtained was used to estimate the amount of drugs present in a pharmaceutical dosage form.

Formulation development of bilayer tablets

Development of bilayer tablets of metformin hydrochloride and gliclazide was carried out in two stages. Blends of the SR layer of metformin hydrochloride (layer 1) and gliclazide (layer 2) were prepared and initially compressed separately for preliminary evaluations. After optimization of an individual layer, the bilayer tablet was prepared using selected formulas.

Formulation of metformin hydrochloride layer (layer-1)

Metformin hydrochloride is a very moisture-sensitive drug. Hence, various formulations of metformin hydrochloride were prepared by non-aqueous wet granulation (M1-M4) and direct compression (M5-M7). In formulations, (M1-M4) HPMC K100M was used as a retardant. All the ingredients passed through a 60-mesh sieve. A blend of all ingredients was mixed thoroughly in a rapid mixer granulator resulting in phase homogenization and granulated manually with a binder solution, which was prepared by dissolving povidone K30 in isopropyl alcohol. The wet masses were passed through a 12 mesh sieve and the wet granules produced was initially air-dried for 10 min and finally at 45-50°C in a tray dryer for 2 h until the LOD (Loss on drying) of granules reached moisture limit between 2-3% w/w. The dried granules sieved by 16 mesh sieve were lubricated with magnesium stearate (which was sifted through 60 mesh) and compressed to tablets. Formulations (F5-F7) were prepared using polyox WSR coagulant as retardant along with other
excipients. The ingredients passed through a 60-mesh sieve, mixed thoroughly in a rapid mixer granulator, lubricated and compressed. Before compression, the final blend was evaluated for its flow and compressibility characteristics. All the tablets compressed using Cadmach single punch tablet compression machine with 12 mm concave punch were stored in airtight containers for further study [15, 16].

The composition of the metformin hydrochloride sustained release layer is mentioned in table 1.

**Table 1: Composition of metformin hydrochloride layer**

| Ingredients (mg)               | Formulation code |
|-------------------------------|------------------|
| Metformin hydrochloride       | M1               |
| HPMC K100M                    | 500              |
| HPMC K15M                     | 120              |
| PolykWSR coagulant            | -                |
| MCC                           | 140              |
| Mannitol                      | -                |
| PVP K 30                      | -                |
| IPA                           | qs               |
| HPMC: Hydroxypropylmethylcellulose, MCC: Microcrystalline cellulose, PVP: Polyvinyl pyrrolidone, IPA: Isopropyl alcohol, qs: quantity sufficient. Total weight per tablet: 800 mg|

**Formulation of gliclazide layer (layer-2)**

Various formulations of gliclazide (G1-G9) were prepared with different ratios of Hydroxy Propyl Methyl Cellulose of different grades like HPMC-K100M, HPMC-K15M, HPMC-K100M and other ingredients by taking appropriate quantities as mentioned in table 2. The granules were evaluated for pre-compression parameters. The composition of the gliclazide layer is mentioned in table 2.

**Table 2: Composition of gliclazide layer**

| Ingredients (mg) | Formulation code |
|------------------|------------------|
| Gliclazide       | G1               |
| DCP              | 60               |
| HPMC K4M         | 90               |
| HPMC K15M        | 20               |
| PVP K30          | 6                |
| SA               | 20               |
| Magnesium stearate| 4               |
| DCP: Dicalcium phosphate, HPMC: Hydroxy Propyl Methyl Cellulose, PVP: Polyvinyl pyrrolidone, IPA: Isopropyl alcohol, qs: quantity sufficient. Total weight per tablet: 200 mg|

**Evaluation of marketed formulation exermet GZ 560**

The marketed product (Exermet GZ 560) was evaluated to determine thickness, weight and dissolution profile following the standard method of testing. The values of these properties are given in table 5.

**Evaluation of post-compression parameters**

**Physicochemical properties of tablets**

The compressed monolithic matrix tablets are characterized for post-compression properties like weight variation, friability, hardness and thickness as per IP and USP standard methods. The weight variation of the tablets was carried out with 20 tablets using an electronic balance (Shimadzu, Japan). Friability was determined using 10 tablets in a Roche friabilator (Pharma Lab, Ahmadabad, India) for 4 min at 25 rpm. For each formulation, the hardness of 10 tablets was evaluated using a hardness tester (Monsanto hardness tester). The thickness of 10 tablets was measured using Vernier Calipers [17, 18].

**Drug content uniformity**

Twenty tablets weighed accurately and finely powdered. The powder equivalent to 500 mg of metformin hydrochloride and 60 mg of gliclazide was transferred into a 100 ml volumetric flask. 50 ml of pH 7.4 buffer was added to the powder and sonicated to dissolve completely. Then the volume made up to 100 ml with buffer and filtered by Whatman filter paper, suitably filtered and analyzed by the reported HPLC method at 261 nm using standard stocks. Each sample was injected filter paper, suitably filtered and analyzed by the reported HPLC method at 261 nm using standard stocks. Each sample was injected six times and the sample retention times were observed in all cases. Retention time about 3.27 min for metformin hydrochloride and 6.12 min for gliclazide observed for stock solution.
Dissolution data analysis

The dissolution profile comparison carried out using the model-independent or model-dependent method. A simple model-independent approach uses a difference factor ($f_1$) and a similarity factor ($f_2$) to compare dissolution profiles.

$$f_1 = \frac{\left(\sum_{t=1}^{n} |R_t - T_t| \right)}{\left(\sum_{t=1}^{n} R_t \right)} \times 100$$

$$f_2 = 50 \times \log \left(\frac{1}{n} \sum_{t=1}^{n} (R_t - T_t)^2 \right)^{\frac{1}{2}} \times 100$$

Where, $R_t$ and $T_t$ represent the average percent dissolved at time $t$ for reference and test, respectively and $n$ is the number of time points tested.

Dissolution profile considered satisfactory if $f_1$ values lie below 50 (nearing zero) and $f_2$ values lie more than 50 (nearing 100). If the $f_2$ value is between 50-100, the value of the test and the reference are identical. The model-independent method is most suitable for dissolution profile comparison when three to four or more dissolution time points are available [23].

Kinetic model fitting

Dissolution data of the above two methods were fitted in Zero order, First order and Higuchi equations. Based on the slope and $r^2$ values obtained, the mechanism of drug release was determined.

Accelerated stability studies

The accelerated stability testing was conducted to provide evidence on how the quality of a drug substance varies with time under influence of a variety of environmental factors such as temperature, humidity, light and enables recommended storage conditions. The study was conducted by wrapping the bilayer tablets in aluminum foils and kept at 25 °C/60% RH and 40 °C/75% RH. Then the tablets were checked for appearance, thickness, and hardness. In addition, drug content and dissolution studies were performed periodically for 6 mo and compared with initials as per ICH guidelines [26].

RESULTS AND DISCUSSION

Drug-excipient interaction study

The compatibility of the pure drug with its excipients on physical observation exhibited no interaction; therefore, the excipients were selected for formulation. The distinctive melting points were observed for metformin hydrochloride at 224 °C and gliclazide at 182 °C and no evident melting point changes were noted indicating overall compatibility.

FT-IR spectroscopy

The FT-IR spectrum of metformin hydrochloride and gliclazide in formulations was as shown in fig. 3C. FT-IR studies revealed that metformin hydrochloride showed two typical bands at 3371 and 3296/cm due to N-H primary stretching vibrations and a band at 3174/cm due to N-H secondary stretching, and characteristic bands at 624 and 1584/cm assigned to C=N stretching. No significant shifts of reduction in the intensity of the FT-IR bands of metformin hydrochloride were observed which indicates the absence of drug-drug interaction and drug-polymer interaction between metformin hydrochloride and Polyox WSR coagulant.

Hence, these two drugs were selected for the development of sustained-release bilayer tablets and polyox WSR coagulant was selected as a release-retarding agent. An IR spectrum of pure gliclazide shows two characteristic peaks. A peak at 3414.85 cm$^{-1}$ due to NH group and another peak at 1636.79 cm$^{-1}$ due to C=O as observed in fig. 3B showing no interaction indicating overall compatibility with the polymer HPMC K100M and excipients.

Characterization of powder blend

The results of the pre compressional parameters such as bulk density, tapped density angle of repose, Hausner’s ratio and compressibility index of all batches of SR blend containing metformin hydrochloride and gliclazide exhibited good characteristics. All the formulations showed good compressibility and flow properties than pure drugs. The precompression values of metformin hydrochloride and gliclazide blend were indicated in table 3 and table 4 respectively.

Fig. 3: Fourier transform infrared spectrum (A) Metformin hydrochloride (B) Gliclazide (C) Metformin hydrochloride+Gliclazide (D) Metformin hydrochloride+Polyox WSR coagulant (E) Gliclazide+HPMC K 100M
Table 3: Precompression parameters of metformin hydrochloride formulation M1–M7

| Formulation code | Bulk density (g/cm³) | Tapped density (g/cm³) | Compressibility (%) | Hausner’s ratio | Angle of repose (°) |
|------------------|----------------------|------------------------|---------------------|----------------|-------------------|
| M1               | 0.62±0.009           | 0.71±0.038             | 12.8                | 1.14           | 23                |
| M2               | 0.72±0.012           | 0.85±0.08              | 15.8                | 1.18           | 25                |
| M3               | 0.68±0.018           | 0.78±0.027             | 13                  | 1.14           | 25                |
| M4               | 0.62±0.066           | 0.74±0.012             | 16.5                | 1.19           | 22                |
| M5               | 0.61±0.053           | 0.79±0.042             | 22.2                | 1.28           | 28                |
| M6               | 0.62±0.038           | 0.72±0.082             | 13.7                | 1.15           | 20                |
| M7               | 0.66±0.039           | 0.72±0.013             | 9.14                | 1.1            | 18                |

mean±SD, n = 3 SD=Standard deviation

Table 4: Pre compression parameters of gliclazide formulation G1–G8

| Formulation code | Bulk density (g/cm³) | Tapped density (g/cm³) | Compressibility (%) | Hausner’s ratio | Angle of repose (°) |
|------------------|----------------------|------------------------|---------------------|----------------|-------------------|
| G1               | 0.65±0.072           | 0.79±0.082             | 17.6                | 1.21           | 20.6              |
| G2               | 0.54±0.012           | 0.69±0.032             | 22                  | 1.28           | 21.7              |
| G3               | 0.57±0.019           | 0.71±0.015             | 19.6                | 1.24           | 19.7              |
| G4               | 0.52±0.062           | 0.68±0.082             | 22.4                | 1.29           | 19.3              |
| G5               | 0.53±0.083           | 0.68±0.029             | 22.5                | 1.29           | 22.6              |
| G6               | 0.54±0.022           | 0.65±0.072             | 16.3                | 1.29           | 20.1              |
| G7               | 0.56±0.014           | 0.69±0.012             | 19.8                | 1.24           | 18.7              |
| G8               | 0.52±0.092           | 0.68±0.062             | 22.4                | 1.29           | 19.8              |

mean±SD, n = 3

Table 5: Physical evaluation of the innovator

| Brand name         | Exemget GZ 560 |
|--------------------|----------------|
| Manufacturer       | Cipla          |
| Composition        | Metformin hydrochloride–500 mg Glipizide–60 mg |
| Total weight of the tablet | 1000 mg |
| Thickness | 5.3 mm |
| Drug content | Metformin hydrochloride–99.97±0.11% Glipizide 99.96±0.41% |

Evaluation of post-compression parameters of tablets

All tablets appeared smooth and oblong. The weight of the metformin hydrochloride layer was kept constant to 800 mg. All tablet batches qualify the tablet weight variation test and found variation 100±5 % within range; friability below 1%; drug content 90–110% within limit and deviation in thickness found less than 5%. Results of post-compression parameters of metformin hydrochloride tablets were observed in table 6. The optimized metformin hydrochloride formulation was further used to prepare bilayer tablets using different gliclazide formulations. Results of post-compression parameters of bilayer tablets were observed in table 7.

Table 6: Post compression parameters of metformin hydrochloride formulations M1–M7

| Formulation code | Weight variation (mg) | Hardness (Kg/ Cm²) | Thickness (mm) | Friability (%) | Content uniformity % (layer 1) |
|------------------|-----------------------|-------------------|---------------|---------------|-------------------------------|
| M1               | 800±0.19              | 7.5±0.23          | 5.1±0.21      | 0.41±0.002    | 99.28±0.57                   |
| M2               | 800±0.38              | 7.8±0.24          | 5.02±0.15     | 0.68±0.005    | 99.57±0.86                   |
| M3               | 800±0.79              | 8.5±0.23          | 5.04±0.23     | 0.53±0.005    | 99.75±0.36                   |
| M4               | 800±0.74              | 8.9±0.26          | 5.08±0.42     | 0.36±0.008    | 99.78±0.87                   |
| M5               | 800±0.56              | 8.3±0.93          | 5.11±0.33     | 0.86±0.002    | 98.68±0.28                   |
| M6               | 800±0.49              | 8.5±0.27          | 5.04±0.13     | 0.72±0.004    | 98.83±0.39                   |
| M7               | 800±0.68              | 8.4±0.23          | 5.03±0.26     | 0.93±0.007    | 99.95±0.26                   |

mean±SD, n = 3

Table 7: Post compression parameters of gliclazide formulation G1–G8

| Formulation code | Weight variation (mg) | Hardness (Kg/ Cm²) | Thickness (mm) | Friability (%) | Content uniformity % (Layer 2) |
|------------------|-----------------------|-------------------|---------------|---------------|-------------------------------|
| G1               | 200±0.67              | 7.5±0.23          | 2.11±0.03     | 0.54±0.009    | 98.5±0.83                    |
| G2               | 200±0.29              | 6.7±0.28          | 2.01±0.83     | 0.67±0.0021   | 99.4±0.75                    |
| G3               | 200±0.57              | 7.4±0.83          | 2.13±0.12     | 0.49±0.0024   | 99.3±0.62                    |
| G4               | 200±0.75              | 8.5±0.26          | 2.17±0.08     | 0.81±0.027    | 99.7±0.69                    |
| G5               | 200±0.38              | 8.5±0.73          | 2.04±0.42     | 0.32±0.037    | 99.5±0.62                    |
| G6               | 200±0.32              | 8.0±0.27          | 2.08±0.16     | 0.65±0.0073   | 98.6±1.04                    |
| G7               | 200±0.61              | 8.5±0.74          | 2.04±0.28     | 0.87±0.028    | 98.6±1.67                    |
| G8               | 200±0.85              | 8.6±0.51          | 2.03±0.34     | 0.62±0.0065   | 99.7±0.19                    |

mean±SD, n = 3
**In vitro dissolution studies of the sustained-release layer containing metformin hydrochloride**

All the formulations subjected to *in vitro* dissolution studies revealed that tablets containing release modifiers exhibited sustained release of metformin hydrochloride and gliclazide. The dissolution profile of formulations containing metformin hydrochloride was represented in fig. 4. The dissolution profile of metformin hydrochloride formulation revealed that M1-M3 formulations released the drug completely by the end of 12 h, which is probably due to faster dissolution of the highly water-soluble drug from the core and its diffusion out of the matrix forming the pores for the entry of solvent molecules. A suitable sustained-release formulation should release the required amount of drug in the initial hour, followed by slow release. Formulation M4 (30% HPMC K100M) exhibited the slowest dissolution profile which was consistent with USP specification. In contrast, the release of metformin hydrochloride from formulation M5-M7 prepared using polyox WSR coagulant was extended up to 24 h. Batch M7 prepared by direct compression method using polyox WSR coagulant (25%) exhibited a good drug release profile. Data of comparison of formulations M4 and M7 with innovator by similarity and dissimilarity factor represented in table 8 reveals that M7 is the promising batch and selected as the best formulation for further studies.

**Table 8: Comparison of formulations with innovator by similarity and dissimilarity factor**

| Formulation | f2 value | f1 value |
|-------------|----------|----------|
| M4          | 72.05    | 3.6      |
| M7          | 79.95    | 2.36     |

**Sustained-release layer containing gliclazide**

The dissolution profile of gliclazide formulations was represented in fig. 5. Formulation G3 and G6 displayed a cumulative release of nearly 98.7% and 99.6% in 12 h and 16 h respectively where 40% of polymers HPMC K4M and K15M were employed. In contrast, the formulation G8 exhibited a better-controlled release profile of 99.8% at 24 h as represented in fig. 5.

**Fig. 4: In vitro dissolution profile of Metformin hydrochloride formulation M1-M7 and innovator**

**Fig. 5: In vitro dissolution profile of gliclazide formulation G1-G8 and Innovator**

Here, the polymer HPMC K100M showed a better rate of retardant ability than the above two variants at a lesser concentration. The hydration rate of HPMC increases with an increase in the Hydroxyl Propyl content and the solubility of HPMC is pH-independent [22]. The water-repelling property of higher variants of HPMC retarded the drug release from the matrix by preventing the penetration of solvent molecules. HPMC K100M was judiciously selected in preparation due to its profound ability to form a strong viscous gel on contact with aqueous media, which helps in controlling the delivery of highly water-soluble drugs [24].

**Final compression of bilayer tablets**

Based on results of *in vitro* dissolution studies batch M7 of metformin hydrochloride and batch G8 of gliclazide were selected to prepare bilayer tablets. Initially, the metformin hydrochloride blend was poured into the die cavity and compressed with moderate force. Then the upper punch was lifted and the gliclazide granules were poured in the die cavity, containing initially compressed layer 1 and compressed with full force to form a bilayer tablet of 1000 mg with a hardness of 7-8 Kg/Cm² using Cadmac single punch compression machine with 12 mm concave punch and die [26]. The dissolution profiles of the individual layer in the final formulation were compared with the innovator (Exermet GZ 560) and results were represented in fig. 6. From the graphs, it is evident bilayer tablet shows a similar release pattern as Exermet GZ 560 with a good similarity factor 79.95 and 73.62 for metformin hydrochloride and gliclazide respectively. The post-compression parameters of the bilayer tablets were found to be within the limits.
**Drug release kinetics**

The release mechanism of metformin hydrochloride and gliclazide from bilayered optimized formulation was studied by fitting the data obtained from *in vitro* release studies into zero-order, first-order, Higuchi and Korsmeyer-Peppas models.

It is evident from fig. 8 that a linear relationship was obtained with 'r' value close to unity and higher than 'r' obtained from the zero-order equation for optimized bilayer formulation of metformin hydrochloride and gliclazide, showing that the release is an apparent first-order process. This indicates that the amount of drug released is dependent on the matrix drug load.

The linearity of the Higuchi plot indicates that the release process of metformin hydrochloride and gliclazide from the optimized formulation is diffusion controlled. The slope values in the Korsmeyer-Peppas equation in fig. 10 indicate that the diffusion mechanism involved was Fickian in the case of metformin hydrochloride and the Non-Fickian in the case of Gliclazide in the final bilayer tablet. Thus, the sustained-release bilayer tablet formulation displayed the release of the required quantity of drug with predetermined kinetics to maintain an effective drug plasma concentration.
Stability studies
Stability studies of sustained-release bilayer tablets developed in this investigation were carried out for 6 mo in specified conditions. The results reveal that there was no significant change in physical characteristics, % drug content and % drug release in 24 h. when stored at 40±2°C/75±5% RH. Therefore, it has been considered that formulation having good stability.

CONCLUSION
The monolith diffusion-controlled bilayer tablets of metformin hydrochloride and gliclazide were successfully developed using the lesser concentration of polyox WSR coagulant and HPMC K 100M as retardant polymers respectively. In vitro release profiles revealed that 99.93% of the metformin hydrochloride and 99.65% gliclazide were released from the final optimized formulation at the end of 24 h. The drug release follows first order and is diffusion controlled. Therefore, the designed formulation offers improved patient compliance and convenience with better postprandial hyperglycemic control with once-a-day dosing. The sustained release of the drug up to 24 h regulates antidiabetic activity round the clock with minimal side effects.

ACKNOWLEDGEMENT
The authors would like to thank the Principal of Andhra University College of Pharmaceutical Sciences for providing their support, facilities, and guidance in this research work.

FUNDING
Nil

AUTHORS CONTRIBUTIONS
All authors have contributed equally.

CONFLICT OF INTERESTS
The authors declare no conflict of interests.

REFERENCES
1. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KY. Goodman and gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill; 2011.
2. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol 2016;12:357-70.
3. Rajni J, Piyush J, Poorva J. A review on treatment and prevention of diabetes mellitus. Int J Curr Pharm Res 2016;8:16-8.
4. International Diabetes Federation. Atlas of Diabetes. 5th ed. Belgium: International Diabetes Federation; 2011.
5. World Health Organization Global report on diabetes 2016.
6. International Diabetes Federation, IDF. Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017. Available from: http://www.diabetesatlas.org. [Last accessed on 23 Jan 2019]
7. Jadhav VD, Patil JR, Patil PP. Formulation and evaluation of bilayered tablet of piracetam and vinpocetine. J Chem Pharm Res 2011;3:423-31.
8. Shiyan B, Gattani S, Surana S. Formulation and evaluation of bilayer tablet of metcloproamide hydrochloride and ibuprofen. AAPS PharmSciTech 2008;9:818-27.
9. Rashmi MB, Prakash R, Abbulu K, Sudarshan S, Nawres A Taha, Suresh C. Statistical design and development of a liquid oral floating in situ gel of metformin hydrochloride for sustained release: pharmacodynamics and toxicity (histopathology) studies. Int J Appl Pharm 2019;11:96-104.
10. Park K. Controlled drug delivery systems: past forward and future back. J Controlled Release 2014;190:3-8.
11. Al-Omary FA. Gliclazide. Profiles Drug Subst Excipients Relat Methodol 2017;42:125-92.
12. Vishwakarma AG, Pawan AG, Mogul RT. Bilayer tablet—a new approach in oral drug delivery system. Int J Pharm Tech Res 2016;8:1416-26.
13. Lieberman HA, Lachman L. Pharmaceutical dosage forms. Vol. 1. New York: 2nd edition CRC Press; 1989.
14. Rahul S Solunke, Uday RB, Krishna M, Madhuri T Deshmukh, Raj Kumar V Shete. Formulation and evaluation of gliclazide nanosponges. Int J Appl Pharm 2019;11:16-18.
15. Wadher KJ, Kalde RB, Umekar MJ. Formulation and evaluation of sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers. Indian J Pharm Sci 2011;73:208-15.
16. Purushottam, Gangane S, Manjesh M Kadam, Debashri KM, Nilesh M, Mahajan U, et al. Design and formulating gliclazide solid dispersion immediate-release layer and metformin sustained release layer in bilayer tablet for the effective postprandial management of diabetes mellitus. Int J Pharm Sci Res 2018;9:3743-56.
17. Nanjwade BG, Manvi FZ. Formulation of extended-release metformin hydrochloride matrix tablets. Trop J Pharm Res 2011;10:375-83.
18. Indian Pharmacopoeia. Vol. 2. New Delhi: Controller of Publication, Govt. of India, Ministry of Health and Family Welfare; 1996. p. 736.
19. Kalpesh W, Sachin K, Kamlesh D Mali, Satish KP, Dheeraj TB. Design and evaluation of bilayer tablets of glimepiride and metformin hydrochloride with the combination of hydrophilic and hydrophobic polymers by hot-melt extrusion of bilayer tablets of glimepiride and metformin. Asian J Pharm Clin Res 2014;7:300-4.
20. Padmaja. Formulation and evaluation of metformin HCl sustained-release oral matrix tablets. Asian J Pharm Clin Res 2011;4:350.
21. Gandhimathi M, Ananda K, Cherylan A, Ravi TK. Simultaneous estimation of metformin and gliclazide in tablets using reverse phase high-performance liquid chromatography. Indian J Pharm Sci 2003;65:530-1.
22. Ediga S. A new simple RP-HPLC method for simultaneous estimation of metformin HCl and glipizide tablet dosage form. Int J Pharm Biol Sci 2012;2:277-83.
23. Hirochi TA. Mechanism of sustained action medication. J Pharm Sci 1963;52:1145-9.
24. Sudipta D, Arnab S, Himadri SDE. Formulation, in vitro release kinetics and stability interpretation of sustained-release tablets of metformin hydrochloride. Int J Pharm Sci 2015;7:418-22.
25. Mathews BA. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 1999;25:831-5.
26. Santhosh K, Bhagwat P, Prachi U. Bilayer tablet of tramadol and gabapentin for combination pharmacotherapy of neuropathic pain: development and characterization. Int J Appl Pharm 2015;10:100-7.